News

August 7, 2023

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

August 4, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

August 1, 2023

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

July 19, 2023

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

July 17, 2023

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

July 13, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

June 17, 2023

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

June 7, 2023

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 22, 2023

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries